Search

Three Million is a Step Forward, But Not Enough

In response to the the US State Department, Global Fund, and Gilead announcement of increased volume commitments for lenacapavir (LEN) for HIV prevention, AVAC and Access Bridge call for global leaders to do even more to ensure meaningful, expanded access.

Three Million is a Step Forward, But Not Enough

In response to the the US State Department, Global Fund, and Gilead announcement of increased volume commitments for lenacapavir (LEN) for HIV prevention, AVAC and Access Bridge call for global leaders to do even more to ensure meaningful, expanded access.

Roundup: The latest resources powering HIV & STI advocacy

Advocates are driving progress in HIV and STI prevention—guiding research, expanding access, holding powerful actors accountable and elevating community priorities. This roundup highlights advocacy in action, from new resources and policy frameworks to updates on the rollout of the latest prevention tools.

Source of Lenacapavir for PrEP Supply to Early Adopter Countries

The Global Fund, with support from CIFF, and PEPFAR have jointly committed to reaching up to two million people with injectable lenacapavir for PrEP over three years. Supply of LEN began arriving in countries in late 2025 with service delivery planned to start in early 2026.

Potential Lenacapavir Supply, 2026-28

Lenacapavir has the potential to reach millions — and the momentum is building. Using the current oral PrEP market as a baseline, this graphic estimates what demand for LEN could look like through 2028 and shows how current donor commitments stack up against that opportunity.

Potential Demand for LEN for PrEP

The top 16 PrEP markets, based on 2024 oral PrEP initiations and the possible 2026 injectable market, assuming 60% of new PrEP users choose an injectable, as seen in implementation studies.

Overview of Key LEN Dose, Volumes, Timelines and Prices

AVAC developed this summary of key information related to LEN to help drive transparency from all stakeholders and, hopefully, to accelerate the speed, scale and equity in its introduction.

Global Health Watch: Proposed US budget cuts, HIV supply chain disruptions, Global Fund commitments, new attempt to weaken US vax policy

Proposed US budget cuts, HIV supply chain disruptions, evolving Global Fund commitments, and a renewed attempt to undermine US vaccine policies highlight a landscape under rapid shifts this week.

Jessica Salzwedel

AVAC and Partners Launch New STI Advocacy Agendas in Kenya, South Africa and Zimbabwe

AVAC and partners are proud to share three new national sexually transmitted infections (STIs) advocacy agendas for Kenya, South Africa and Zimbabwe, providing coordinated agendas to elevate STIs as a national health priority and accelerate actions on R&D and delivery of STI vaccines, diagnostics, prevention and care.